IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the audio recording of its earnings call for Q2 & H1 FY27 financial results, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced its Q2 & H1 FY27 financial results, showing a 40.1% YoY increase in revenue from operations to ₹795.0 Cr, with EBITDA and PAT margins improving to 14.4% and 8.1% respectively.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced its unaudited financial results for the quarter and half year ended 30th September 2026, showing a net profit of Rs. 87.25 crore for the quarter and Rs. 174.02 crore for the half year, with a total comprehensive income of Rs. 63.69 crore for the quarter and Rs. 127.14 crore for the half year.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd reported its Q2 & H1 FY27 results, recording highest-ever quarterly revenue, EBITDA & PAT. The company's Pharmaceuticals business performed well, backed by healthy demand across the portfolio, while the Chemicals business also recorded a significant improvement.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced its unaudited financial results for the quarter and half year ended 30th September 2026, with revenue from operations at ₹795.03 crore and total income at ₹800.54 crore.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has submitted its unaudited financial results for the quarter and half year ended 30th September 2026, with revenue from operations at ₹795.03 crore and total income at ₹800.54 crore.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/investor conference call to discuss the financial performance for Q2 & H1 FY27, to be held on 2nd November 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 30/10/2026 to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended 30th September 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the submission of a newspaper publication regarding a special window for transfer-cum-dematerialization of physical shares, as per SEBI Circular No. H0/38/13/11 (2)2026-MIRSO-PODN3750/2026 dated 30th January 2026. The company has informed shareholders that a special window has been opened from February 05, 2026, to February 04, 2027, for re-lodging transfer deeds for physical shares that were not lodged prior to 1st April 2019, and that shares re-lodged during this window will be processed only in dematerialized form.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has received a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026, confirming the dematerialization of physical share certificates.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Active Pharmaceutical Ingredient (API) product 'Fenofibrate - Process II'. This is in addition to the existing CEP held by the company for 'Fenofibrate'. The new CEP strengthens the company's regulatory portfolio and supports its ability to cater to regulated markets for Fenofibrate.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective from October 1, 2026, until the expiry of 48 hours after the declaration of the financial results for the quarter and half year ended September 30, 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has received REACH certification/registration for its product 'Triacetin' under the EU-REACH framework, enabling the company to export the product across all European Union countries.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on 29th September 2026, where the management will discuss past financial results and publicly available information.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on September 28, 2026, where the company's management will discuss past financial results and publicly available information.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the voting results and scrutinizer's report for its 39th Annual General Meeting, which was held on September 2, 2026. The meeting was attended by 87 public shareholders through video conferencing, and 5 promoter shareholders. Three resolutions were passed, including the adoption of the standalone and consolidated audited financial description of the company for the financial year ended March 31, 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd held its 39th Annual General Meeting (AGM) on September 2, 2026, through video conferencing. The meeting was attended by the Chairman, Mr. Rajender Mohan Malla, and the Company Secretary, Mr. Abhay Raj Singh. The AGM approved the standalone and consolidated audited financial statements for the financial year ended March 31, 2026. The meeting also ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The voting results were announced, and the reports of the statutory auditors and secretarial auditors did not contain any qualifications or comments.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on 3rd September 2026, organized by Phillip Capital (India) Private Limited. The meeting will be held in person and will focus on past financial results and publicly available information. No unpublished price-sensitive information will be disclosed.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has reported a strong Q1 FY27 performance, driven by healthy demand across key products, improved capacity utilization, favorable product mix, and operational efficiency. The company has made progress in diversifying its API portfolio beyond ibuprofen, with non-ibu products contributing 43% of pharmaceutical revenue in Q1 FY27, up from 36% in Q1 FY26. The company's international business also strengthened during the quarter, with exports increasing to 28.5% of revenue.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the submission of newspaper publication regarding a special window for transfer-cum-dematerialisation of physical shares, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.